Ellen Burnham
Concepts (549)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 38 | 2025 | 821 | 6.560 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 650 | 1.970 |
Why?
| | Respiratory Insufficiency | 10 | 2025 | 326 | 1.930 |
Why?
| | Lung | 19 | 2025 | 4134 | 1.740 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 125 | 1.660 |
Why?
| | Cannabis | 5 | 2025 | 512 | 1.310 |
Why?
| | Intensive Care Units | 20 | 2025 | 868 | 1.300 |
Why?
| | Pneumonia | 9 | 2023 | 656 | 1.290 |
Why?
| | Ethanol | 11 | 2022 | 629 | 1.280 |
Why?
| | Acute Lung Injury | 10 | 2022 | 304 | 1.260 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 330 | 1.220 |
Why?
| | Critical Illness | 21 | 2024 | 837 | 1.180 |
Why?
| | Marijuana Smoking | 3 | 2025 | 263 | 1.090 |
Why?
| | Sepsis | 6 | 2020 | 616 | 1.070 |
Why?
| | Gene Expression | 3 | 2020 | 1491 | 1.030 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 396 | 1.010 |
Why?
| | Cytokines | 9 | 2025 | 2098 | 0.960 |
Why?
| | Critical Care | 10 | 2021 | 649 | 0.950 |
Why?
| | Survivors | 8 | 2025 | 501 | 0.900 |
Why?
| | Middle Aged | 72 | 2025 | 34434 | 0.880 |
Why?
| | Inflammation Mediators | 4 | 2016 | 519 | 0.880 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 89 | 0.840 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 410 | 0.830 |
Why?
| | Acetates | 2 | 2021 | 79 | 0.830 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 57 | 0.830 |
Why?
| | Stem Cells | 5 | 2015 | 602 | 0.800 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 169 | 0.800 |
Why?
| | Adult | 66 | 2025 | 39177 | 0.780 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 400 | 0.780 |
Why?
| | Hospital Mortality | 7 | 2025 | 924 | 0.770 |
Why?
| | Mentors | 4 | 2014 | 210 | 0.770 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 184 | 0.760 |
Why?
| | Humans | 130 | 2025 | 141187 | 0.760 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 573 | 0.750 |
Why?
| | Smoking | 8 | 2021 | 1601 | 0.750 |
Why?
| | Lung Diseases | 3 | 2021 | 794 | 0.740 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 271 | 0.710 |
Why?
| | Male | 80 | 2025 | 69783 | 0.680 |
Why?
| | Female | 82 | 2025 | 75515 | 0.680 |
Why?
| | Hospitalization | 9 | 2023 | 2255 | 0.670 |
Why?
| | Behavior | 1 | 2021 | 93 | 0.670 |
Why?
| | Thalamus | 2 | 2021 | 120 | 0.660 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 214 | 0.660 |
Why?
| | Glycerophospholipids | 4 | 2024 | 36 | 0.660 |
Why?
| | Respiration, Artificial | 13 | 2025 | 683 | 0.660 |
Why?
| | Case-Control Studies | 14 | 2022 | 3588 | 0.650 |
Why?
| | Burnout, Professional | 4 | 2022 | 455 | 0.630 |
Why?
| | Hallucinogens | 1 | 2021 | 112 | 0.610 |
Why?
| | Cigarette Smoking | 2 | 2020 | 103 | 0.600 |
Why?
| | RNA, Messenger | 5 | 2020 | 2828 | 0.580 |
Why?
| | Glutathione | 5 | 2016 | 356 | 0.580 |
Why?
| | Antioxidants | 4 | 2016 | 595 | 0.570 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 47 | 0.560 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 286 | 0.560 |
Why?
| | Epithelial Cells | 4 | 2021 | 1110 | 0.550 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 562 | 0.550 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 120 | 0.550 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 25 | 0.540 |
Why?
| | Tobacco Products | 1 | 2019 | 129 | 0.540 |
Why?
| | Physicians, Women | 1 | 2019 | 87 | 0.540 |
Why?
| | Inflammation | 8 | 2025 | 2890 | 0.540 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 92 | 0.530 |
Why?
| | Biomedical Research | 2 | 2021 | 703 | 0.500 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 276 | 0.500 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 12 | 0.490 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 52 | 0.490 |
Why?
| | Marijuana Abuse | 1 | 2018 | 231 | 0.470 |
Why?
| | Alcohol Drinking | 6 | 2025 | 834 | 0.470 |
Why?
| | Burns | 4 | 2024 | 349 | 0.470 |
Why?
| | Azithromycin | 1 | 2015 | 98 | 0.450 |
Why?
| | Tomography | 2 | 2025 | 45 | 0.440 |
Why?
| | Electric Impedance | 2 | 2025 | 111 | 0.440 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1049 | 0.420 |
Why?
| | Professional Autonomy | 1 | 2013 | 31 | 0.420 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 178 | 0.410 |
Why?
| | Research Support as Topic | 2 | 2011 | 119 | 0.410 |
Why?
| | Aged | 33 | 2025 | 24574 | 0.400 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2746 | 0.400 |
Why?
| | Cells, Cultured | 8 | 2018 | 4208 | 0.400 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 889 | 0.400 |
Why?
| | Bronchoscopy | 3 | 2023 | 226 | 0.390 |
Why?
| | Oxidative Stress | 5 | 2017 | 1330 | 0.390 |
Why?
| | Retrospective Studies | 23 | 2025 | 16273 | 0.380 |
Why?
| | Immunity, Innate | 1 | 2018 | 852 | 0.380 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 22 | 0.370 |
Why?
| | Asthma | 2 | 2022 | 1913 | 0.360 |
Why?
| | Academic Medical Centers | 2 | 2014 | 528 | 0.350 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 270 | 0.350 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 567 | 0.340 |
Why?
| | Biomarkers | 14 | 2024 | 4174 | 0.340 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2599 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 337 | 0.330 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.320 |
Why?
| | Malondialdehyde | 2 | 2021 | 29 | 0.320 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.320 |
Why?
| | Personnel Selection | 1 | 2011 | 86 | 0.310 |
Why?
| | Muscular Diseases | 3 | 2017 | 112 | 0.310 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 96 | 0.310 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 82 | 0.310 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 110 | 0.300 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1865 | 0.300 |
Why?
| | Cohort Studies | 13 | 2020 | 5799 | 0.300 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 127 | 0.290 |
Why?
| | Smokers | 2 | 2021 | 144 | 0.290 |
Why?
| | Hypoxia | 3 | 2025 | 1164 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 92 | 0.280 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.270 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 239 | 0.270 |
Why?
| | Airway Extubation | 3 | 2013 | 60 | 0.270 |
Why?
| | Sexism | 2 | 2019 | 68 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 276 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 156 | 0.260 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.260 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 189 | 0.260 |
Why?
| | Pilot Projects | 6 | 2025 | 1820 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1250 | 0.260 |
Why?
| | Endothelial Cells | 4 | 2011 | 816 | 0.260 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1490 | 0.260 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 235 | 0.250 |
Why?
| | Deglutition Disorders | 3 | 2013 | 148 | 0.250 |
Why?
| | Fibronectins | 1 | 2007 | 135 | 0.250 |
Why?
| | APACHE | 4 | 2013 | 64 | 0.250 |
Why?
| | Young Adult | 13 | 2024 | 13673 | 0.240 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 156 | 0.240 |
Why?
| | Marijuana Use | 2 | 2022 | 221 | 0.240 |
Why?
| | Administration, Inhalation | 3 | 2025 | 596 | 0.240 |
Why?
| | Preoperative Care | 1 | 2008 | 371 | 0.240 |
Why?
| | Risk Factors | 16 | 2020 | 10438 | 0.240 |
Why?
| | Immunity, Cellular | 2 | 2018 | 269 | 0.240 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1171 | 0.230 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 10 | 0.230 |
Why?
| | Anesthesiology | 1 | 2008 | 169 | 0.230 |
Why?
| | Pediatrics | 1 | 2013 | 1094 | 0.230 |
Why?
| | United States | 16 | 2025 | 15220 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 29 | 0.230 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 55 | 0.230 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 374 | 0.230 |
Why?
| | Arachidonic Acids | 1 | 2025 | 63 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 371 | 0.230 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 45 | 0.230 |
Why?
| | Flow Cytometry | 2 | 2024 | 1197 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 89 | 0.220 |
Why?
| | Endocannabinoids | 1 | 2025 | 69 | 0.220 |
Why?
| | Dysbiosis | 2 | 2024 | 180 | 0.220 |
Why?
| | Immunity | 1 | 2025 | 140 | 0.220 |
Why?
| | E-Selectin | 1 | 2004 | 57 | 0.210 |
Why?
| | Bacterial Proteins | 1 | 2010 | 911 | 0.210 |
Why?
| | Quality of Life | 2 | 2013 | 2999 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 878 | 0.210 |
Why?
| | Patient Discharge | 3 | 2024 | 932 | 0.210 |
Why?
| | Anticoagulants | 2 | 2019 | 675 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2022 | 7856 | 0.200 |
Why?
| | Patient Admission | 1 | 2025 | 203 | 0.200 |
Why?
| | Interleukin-1beta | 2 | 2017 | 380 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 329 | 0.200 |
Why?
| | Shock, Septic | 2 | 2022 | 210 | 0.200 |
Why?
| | Internship and Residency | 1 | 2013 | 1235 | 0.200 |
Why?
| | Interferons | 2 | 2016 | 195 | 0.190 |
Why?
| | Lung Injury | 2 | 2016 | 227 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 257 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.190 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 23 | 0.190 |
Why?
| | Epithelium | 2 | 2021 | 316 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 30 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 3292 | 0.180 |
Why?
| | Fibroblasts | 3 | 2013 | 1020 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 440 | 0.180 |
Why?
| | Double-Blind Method | 4 | 2014 | 1983 | 0.180 |
Why?
| | Interleukin-8 | 3 | 2018 | 273 | 0.180 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.180 |
Why?
| | Delirium | 1 | 2023 | 105 | 0.180 |
Why?
| | Societies, Medical | 2 | 2025 | 855 | 0.170 |
Why?
| | Cell Count | 2 | 2015 | 326 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.170 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.170 |
Why?
| | Feces | 1 | 2024 | 504 | 0.170 |
Why?
| | Neutrophils | 3 | 2017 | 1282 | 0.170 |
Why?
| | Physicians | 3 | 2022 | 934 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 367 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1653 | 0.160 |
Why?
| | Phagocytosis | 2 | 2014 | 388 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 346 | 0.160 |
Why?
| | Animals | 18 | 2025 | 37657 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1662 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.160 |
Why?
| | Capacity Building | 1 | 2020 | 62 | 0.160 |
Why?
| | Permeability | 2 | 2012 | 166 | 0.160 |
Why?
| | Career Choice | 2 | 2012 | 232 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1116 | 0.160 |
Why?
| | Chemokines | 2 | 2018 | 228 | 0.160 |
Why?
| | Cardiology | 1 | 2022 | 279 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 84 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 636 | 0.150 |
Why?
| | Prevalence | 3 | 2025 | 2772 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Disaster Planning | 1 | 2020 | 97 | 0.150 |
Why?
| | Needs Assessment | 1 | 2021 | 382 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2022 | 295 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.150 |
Why?
| | Wounds and Injuries | 1 | 2006 | 891 | 0.150 |
Why?
| | Macrolides | 1 | 2019 | 67 | 0.150 |
Why?
| | Pyridines | 2 | 2010 | 510 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 951 | 0.150 |
Why?
| | Brain | 3 | 2021 | 2858 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 434 | 0.140 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 344 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Length of Stay | 4 | 2020 | 1254 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 25 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 84 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 176 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 961 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2574 | 0.140 |
Why?
| | Hospitals, University | 2 | 2015 | 175 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 99 | 0.130 |
Why?
| | Pyrazoles | 1 | 2001 | 443 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 117 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 259 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 175 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 968 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 65 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 987 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 176 | 0.130 |
Why?
| | Cystine | 1 | 2016 | 18 | 0.130 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 497 | 0.130 |
Why?
| | Interleukin-10 | 1 | 2018 | 310 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 550 | 0.130 |
Why?
| | Treatment Outcome | 9 | 2022 | 11120 | 0.120 |
Why?
| | Interleukin-6 | 2 | 2018 | 792 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1336 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 99 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4404 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1100 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 14 | 0.120 |
Why?
| | Hospitalists | 1 | 2020 | 248 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5200 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 725 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 339 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 854 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 316 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 283 | 0.120 |
Why?
| | RNA Splicing | 1 | 2017 | 270 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 181 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1010 | 0.120 |
Why?
| | Inflammasomes | 1 | 2017 | 134 | 0.120 |
Why?
| | Patient Selection | 2 | 2023 | 688 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 232 | 0.120 |
Why?
| | Hospitals | 1 | 2020 | 696 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.120 |
Why?
| | Cysteine | 1 | 2016 | 205 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 142 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 659 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 194 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 178 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 405 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5144 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 292 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1086 | 0.110 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 159 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2892 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1003 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 68 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 20 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1243 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 75 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 97 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 32 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 415 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 40 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3348 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 78 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2793 | 0.100 |
Why?
| | Financial Support | 1 | 2012 | 22 | 0.100 |
Why?
| | Aging | 2 | 2017 | 1892 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2017 | 404 | 0.100 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 23 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1244 | 0.100 |
Why?
| | Logistic Models | 5 | 2017 | 2086 | 0.100 |
Why?
| | Interleukin-12 | 1 | 2013 | 123 | 0.100 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1487 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1129 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 189 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 48 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 312 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 1008 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 19 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 73 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 84 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 323 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 150 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3709 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 82 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 567 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 855 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 689 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7739 | 0.090 |
Why?
| | Capillaries | 2 | 2009 | 125 | 0.080 |
Why?
| | Genetic Testing | 1 | 2013 | 460 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 86 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2025 | 1018 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 17 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1143 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 275 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 459 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 72 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 586 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1470 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 2003 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 96 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 162 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4610 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 767 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1597 | 0.080 |
Why?
| | Peer Group | 1 | 2011 | 247 | 0.080 |
Why?
| | Program Development | 1 | 2011 | 368 | 0.070 |
Why?
| | Mice | 7 | 2022 | 18048 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 242 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 417 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5887 | 0.070 |
Why?
| | Computers | 1 | 2008 | 69 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1936 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 116 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 146 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 565 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 322 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 96 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 331 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2064 | 0.070 |
Why?
| | Schools | 1 | 2011 | 450 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 188 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 151 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 28 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 338 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 437 | 0.070 |
Why?
| | Cell Separation | 3 | 2016 | 317 | 0.070 |
Why?
| | Indicators and Reagents | 1 | 2007 | 110 | 0.070 |
Why?
| | Georgia | 2 | 2004 | 85 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 2058 | 0.070 |
Why?
| | Respiration Disorders | 1 | 2007 | 79 | 0.060 |
Why?
| | Patient Readmission | 3 | 2019 | 706 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 136 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 149 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 70 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1114 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 928 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 208 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 188 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 160 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 655 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5636 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 328 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 117 | 0.060 |
Why?
| | Louisiana | 1 | 2024 | 26 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2013 | 2002 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22007 | 0.050 |
Why?
| | Observation | 1 | 2004 | 56 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 210 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 58 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 760 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 132 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2741 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1444 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 6956 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5929 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 35 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 22 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 362 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 73 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 56 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 88 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.050 |
Why?
| | North America | 1 | 2022 | 306 | 0.040 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 84 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 338 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 134 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 193 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 5 | 0.040 |
Why?
| | Naltrexone | 1 | 2022 | 102 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 200 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 248 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 172 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3068 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 667 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 21 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 857 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1357 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5629 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 60 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 448 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 316 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2794 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4073 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 21 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1816 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 161 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 319 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2018 | 136 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 44 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1516 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 396 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 45 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 26 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 164 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 677 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 100 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 803 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1763 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 715 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 192 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2902 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1396 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 330 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 121 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 379 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 156 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 34 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2797 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 318 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 253 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 149 | 0.030 |
Why?
| | Risk | 1 | 2018 | 904 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 453 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 440 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 196 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 513 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 857 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 557 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 961 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 245 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 215 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1222 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 824 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2070 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 908 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 204 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 25 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1052 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 329 | 0.030 |
Why?
| | Ventilator Weaning | 1 | 2013 | 37 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1319 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 17 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 1018 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 102 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 407 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 319 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 541 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 138 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 133 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 739 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 528 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 355 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 480 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 666 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2239 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 65 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2520 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 417 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 183 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 126 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 217 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 555 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1134 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 101 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 844 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 281 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1748 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 583 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 60 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 559 | 0.020 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 346 | 0.020 |
Why?
| | Amides | 1 | 2010 | 100 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 464 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 704 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 386 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 50 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1768 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 232 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1764 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1081 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 163 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 30 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 21 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 50 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 23 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 50 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 967 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 90 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 64 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 45 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 82 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 771 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 30 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 76 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 69 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1033 | 0.020 |
Why?
| | Child | 2 | 2022 | 22308 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 295 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 463 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 505 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 221 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 356 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 990 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1828 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 556 | 0.020 |
Why?
| | Trauma Centers | 1 | 2009 | 447 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 227 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 339 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 350 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1556 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 539 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 229 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 247 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1498 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 424 | 0.010 |
Why?
| | France | 1 | 2003 | 39 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 85 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 978 | 0.010 |
Why?
| | Washington | 1 | 2003 | 160 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 177 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2504 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1320 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|